Who are Esperion Therapeutics's investors?

Esperion Therapeutics's investors include Aisling Capital, Alta Partners, Arboretum Ventures, ARCHIMED Japan, Asset Management Company, Canaan Partners, HealthCap, Longitude Capital and 2 more.

Where is Esperion Therapeutics headquartered?

Esperion Therapeutics is headquartered in Ann Arbor, US.

Esperion Therapeutics

Ann Arbor, US · 10 known investors

Find your way into Esperion Therapeutics

Biopharma developing HDL-C regulating therapies; listed 2000.

Biotech

Founders & leadership

Antonio M. Gotto, Jr.Named on SEC filing

Tim M. MaylebenNamed on SEC filing

Gilbert S. OmennNamed on SEC filing

Daniel JanneyNamed on SEC filing

Dov A. GoldsteinNamed on SEC filingManaging Partner at Aisling Capital

Roger S. NewtonNamed on SEC filing

Mark E. McGovernNamed on SEC filing

Board

Nicole Vitullo Board directorInvestor at Arboretum Ventures

Patrick Enright Board directorManaging Director at Longitude Capital

Investors · 10

Aisling Capitallisted by Aisling CapitalNew York

How we know: Aisling Capital's portfolio page · Not right? Tell us

Alta Partnerslisted by Alta PartnersJackson · $1M – $12Mvia Dan Janney · led

How we know: Alta Partners's portfolio page · Not right? Tell us

Arboretum Ventureslisted by Arboretum VenturesAnn Arbor · $5M – $15M

How we know: Arboretum Ventures's portfolio page · Not right? Tell us

ARCHIMED Japanlisted by ARCHIMED JapanLyon · $10.8M – $1.1B

How we know: ARCHIMED Japan's portfolio page · Not right? Tell us

Asset Management Companylisted by Asset Management CompanyMenlo Park · $500K – $2M

How we know: Asset Management Company's portfolio page · Not right? Tell us

Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20M

How we know: Canaan Partners's portfolio page · Not right? Tell us

HealthCaplisted by HealthCapStockholm

How we know: HealthCap's portfolio page · Not right? Tell us

Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M

How we know: Longitude Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Oak Investment Partnerslisted by Oak Investment PartnersWilton

How we know: Oak Investment Partners's portfolio page · Not right? Tell us

Oberland Capitallisted by Oberland CapitalNew York · $50M – $300M

Reported raises · per SEC filings

Form D private placements

▶Undisclosed amountofferedJul 2014 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Antonio M. Gotto, Jr.Director
Tim M. MaylebenExecutive Officer, Director
Gilbert S. OmennDirector
Daniel JanneyDirector
Dov A. GoldsteinDirector
Nicole VitulloDirector
Roger S. NewtonDirector
Patrick EnrightDirector
Mark E. McGovernDirector

First sale: Jun 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Esperion Therapeutics (NASDAQ: ESPR) to be acquired for $3.16/share plus CVRsstocktitan.net · Jun 2026

Frequently asked questions

What does Esperion Therapeutics do?: Biopharma developing HDL-C regulating therapies; listed 2000.
Who are Esperion Therapeutics's investors?: Esperion Therapeutics's investors include Aisling Capital, Alta Partners, Arboretum Ventures, ARCHIMED Japan, Asset Management Company, Canaan Partners, HealthCap, Longitude Capital and 2 more.
Where is Esperion Therapeutics headquartered?: Esperion Therapeutics is headquartered in Ann Arbor, US.